Trial Profile
Phase 1,Two-part (Dose Escalation, Dose Expansion), Multicenter,Non-randomized,Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs CA 102 N (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Holy Stone Healthcare
- 04 Nov 2022 Results assessing the safety, PK and preliminary efficacy of CA102N and trifluridine-tipiracil in patients with solid tumors, published in the Investigational New Drugs.
- 20 Sep 2022 Status changed from recruiting to completed.
- 02 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 May 2022.